Latest Breaking News On - புதுப்பிக்கப்பட்டது கட்டம் - Page 1 : comparemela.com

ADC Therapeutics SA: ADC Therapeutics Presents Updated ZYNLONTA (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International Conference on Malignant Lymphoma

ADC Therapeutics SA: ADC Therapeutics Presents Updated ZYNLONTA (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International Conference on Malignant Lymphoma
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesNew jerseyWaals gewestCity ofUnited kingdomMedicina specialisticaLausanne biopDiagnosticae sperimentale universitLoncastuximab tesirineLoncastuximab tesirine loncaEugenia litzJay feingoldBologna istitutoJulien depausAnnie starrLuigi zinzani

FDA Calendar • Benzinga

FDA Calendar • Benzinga
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

United statesCiltacabtagene autoleucelNurown exosomeTecentriq imvokeYervoy ipilimumabOpdivo nivolumabJeffreys millerLoncastuximab tesirineCalifornia society of plastic surgeons annual meetingLupus nephritis at european alliance of associationsAmerican society of clinical oncologyEuropean hematology associationInternational society for pharmacoeconomicsAmerican society of clinical oncology annual meetingInternational society for cellAmerican transplant congress

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), Adaptimmune Therapeutics PLC (NYSE:ADAP) - The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), Adaptimmune Therapeutics PLC (NYSE:ADAP) - The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

United statesAllogene cellectisBristol myers squibb opdivoClovis oncology incMagenta therapeutics incAprea therapeutics incAdvaxis incMerck co incFate therapeutics incTherapeutics incPurple biotech ltdBolt biotherapeutics incLarimar therapeutics incLiminal biosciences incHarpoon therapeutics incAurinia pharmaceuticals inc

Clovis Oncology Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting

Clovis Oncology Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesEcaterinae dumbravaTanya kwanRobert reidPatrickj mahaffyAnna sussmanBreanna burkartClovis oncology incUniversity health networkAmerican society of clinical oncologyUniversity of texas md anderson cancer centerMeeting libraryExchange commissionPrincess margaret cancer centreSarah cannon research institute tennessee oncologyUs oncology network

Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma

(1) Application based on positive Phase 1b/2 data from the CARTITUDE-1 study and follows confirmation of accelerated assessment by the Committee for Medicinal Products for Human Use of the European Medicines Agency The Janssen Pharmaceutical Companies of Johnson Johnson announced today that they have submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of cilta-cel, an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. The application is supported by positive results from the ongoing Phase 1b/2 CARTITUDE-1 study, investigating the safety and efficacy of cilta-cel.

United statesUnited kingdomCiltacabtagene autoleucelNoah reymondJennifer mcintyreCiltacabtagene autoleucel cilta celChristopher deloreficePeter lebowitzMathai mammenHematology am soc hematol educ programAmerican society of clinical oncologyNational cancer instituteInternational myeloma working groupJanssen biotech incAmerican society of hematology annual meetingJanssen pharmaceutical companies